

AMENDMENTS TO THE CLAIMS:

This listing of claims replaces all earlier versions of claims in this application:

Claims 1-3 (Canceled)

4. (Currently Amended) A method for reducing the risk of onset of congestive heart failure in a patient not previously having congestive heart failure and who has an essentially maintained heart function, comprising administering to said patient an effective amount of an angiotensin converting enzyme inhibitor, wherein the patient is a human who exhibits normal or low blood pressure.

Claim 5 (Canceled)

6. (Previously Presented) A method of claim 4, wherein the angiotensin converting enzyme inhibitor is alacepril, alatriopril, altiopril calcium, ancovenin, benazepril, benazepril hydrochloride, benazeprilat, benzoylcaptopril, captopril, captopril-cysteine, captopril-glutathione, ceranapril, ceranopril, ceronapril, cilazapril, cilazaprilat, delapril, delapril-diacid, enalapril, enalaprilat, enapril, epicaptopril, foroxymithine, fosfenopril, fosenopril, fosenopril sodium, fosinopril, fosinopril sodium, fosinoprilat, fosinoprilic acid, glycopril, hemorphin-4, idrapril, imidapril, indolapril, indolaprilat, libenzapril, lisinopril, lyciumin A, lyciumin B, mixanpril, moexipril, moexiprilat, moveltipril, muracein A, muracein B, muracein C, pentopril, perindopril, perindoprilat, pivalopril, pivopril, quinapril, quinapril hydrochloride, quinaprilat, ramipril, ramiprilat, spirapril, spirapril hydrochloride, spiraprilat, spiopril, spiopril hydrochloride, temocapril, temocapril hydrochloride, teprotide, trandolapril, trandolaprilat, utibapril, zabicipril, zabiciprilat, zofenopril, or zofenoprilat.

7. (Previously Presented) The method of claim 6, wherein the angiotensin converting enzyme inhibitor is ramipril, ramiprilat, lisinopril, enalapril, or enalaprilat.

Claims 8-18 (Canceled)

19. (Previously Presented) A method as claimed in claim 4, wherein the angiotensin converting enzyme inhibitor is ramipril.